BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Receives Average Rating of “Buy” from Brokerages

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) has received a consensus recommendation of “Buy” from the five research firms that are covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $32.20.

A number of equities research analysts have recently commented on BLSM shares. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th. HC Wainwright began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 target price for the company. Lifesci Capital began coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $32.00 price target for the company. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $28.00 price objective for the company. Finally, Guggenheim started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 price target on the stock.

BlossomHill Therapeutics Stock Up 3.7%

Shares of NASDAQ:BLSM traded up $0.67 on Tuesday, hitting $18.97. 127,422 shares of the company’s stock were exchanged, compared to its average volume of 224,464. BlossomHill Therapeutics has a 1-year low of $15.25 and a 1-year high of $20.61.

Insider Activity at BlossomHill Therapeutics

In other news, Director John P. Schmid purchased 6,000 shares of the stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the transaction, the director owned 6,000 shares of the company’s stock, valued at approximately $96,000. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the director directly owned 3,614,034 shares in the company, valued at $57,824,544. This trade represents a 9.47% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.